C4 Therapeutics, Inc. (NASDAQ:CCCC) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of C4 Therapeutics, Inc. (NASDAQ:CCCC) have received an average recommendation of “Moderate Buy” from the seven research firms that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have given a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $7.75.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of C4 Therapeutics in a research note on Monday, April 20th.

Institutional Trading of C4 Therapeutics

Large investors have recently made changes to their positions in the company. SummitTX Capital L.P. acquired a new stake in shares of C4 Therapeutics in the 1st quarter valued at about $28,000. CTC Alternative Strategies Ltd. bought a new position in C4 Therapeutics in the 1st quarter valued at about $28,000. Zacks Investment Management bought a new position in C4 Therapeutics in the 3rd quarter valued at about $29,000. Delta Investment Management LLC bought a new position in C4 Therapeutics in the 4th quarter valued at about $38,000. Finally, Virtu Financial LLC bought a new position in C4 Therapeutics in the 4th quarter valued at about $39,000. 78.81% of the stock is currently owned by institutional investors and hedge funds.

C4 Therapeutics Price Performance

Shares of CCCC opened at $4.67 on Wednesday. The stock has a 50-day moving average of $3.60 and a 200-day moving average of $2.81. The company has a market cap of $516.36 million, a PE ratio of -3.92 and a beta of 2.92. C4 Therapeutics has a one year low of $1.39 and a one year high of $5.17.

C4 Therapeutics (NASDAQ:CCCC) last issued its earnings results on Tuesday, May 12th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.05. The company had revenue of $6.15 million during the quarter, compared to the consensus estimate of $4.42 million. C4 Therapeutics had a negative return on equity of 50.68% and a negative net margin of 297.76%. Analysts expect that C4 Therapeutics will post -0.87 EPS for the current fiscal year.

C4 Therapeutics Company Profile

C4 Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degraders. Utilizing its proprietary Controlled Inducible Degradation (CiD) platform, the company seeks to eliminate disease-causing proteins by harnessing the body’s natural protein disposal machinery. This approach aims to address a wide range of oncology and immuno-oncology indications by targeting proteins that have historically been difficult to inhibit with traditional small molecules or antibodies.

The company’s pipeline includes multiple small-molecule degrader candidates advancing through preclinical and clinical stages.